4.5 (318) In stock
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
Current Oncology, Free Full-Text
First-line Atezolizumab Monotherapy Versus Single-agent, 43% OFF
Creative Options, ADT Program, Creative Options
Current Oncology, Free Full-Text
Current Oncology, Free Full-Text, bronstein méier resultado
Frontiers in Oncology
Systematic Review Of The Management Of Brain Metastases, 50% OFF
JCO Oncology Practice
Oncology Board Review: Blueprint Study Guide and Q&A (3rd Revised edition) by Francis P. Worden
Reach Oncologists with Elsevier (US version)
Living with Cancer Resources and Support – February 2022
